UK markets closed

co.don AG (0Q37.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
0.0252-0.2691 (-91.45%)
At close: 05:47PM GMT

co.don AG

Warthestrasse 21
Teltow 14513
Germany
49 3328 43 46 0
https://www.codon.de

Sector(s)
Industry
Full-time employees134

Key executives

NameTitlePayExercisedYear born
Dr. Xing ZhaoManaging DirectorN/AN/AN/A
Mr. Tilmann BurMember of Executive Board257kN/A1965
Mr. Matthias Meissner M.A.Director of Corporate Communications & Investor Relations / Public RelationsN/AN/AN/A
Dr. Ying ZhouManaging DirectorN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

co.don AG, a biopharmaceutical company, develops, produces, and markets biopharmaceutical products for joint preservation and the regenerative treatment of articular cartilage defects worldwide. It offers Spherox, a three-dimensional cartilage cell transplant product that is used to treat cartilage defects in adult knee joints and adolescents; and co.don chondrosphere for the treatment of cartilage defects in the hip, ankle, and shoulder and elbow. co.don AG was founded in 1993 and is headquartered in Teltow, Germany.

Corporate governance

co.don AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.